Eikon Therapeutics, Inc. is a company operating under a 2026 Long-Term Incentive Plan, as described in this SEC filing. The filing excerpt pertains exclusively to the administration of the company's equity incentive plan, including award types such as Options, SARs, Restricted Stock, Restricted Stock Units, Unrestricted Stock, and Performance Awards. No specific products, services, or business operations are described in the provided text.
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-130395 | EDGAR | 153K words |
No 10-Q filings indexed.
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-130449 | EDGAR | 2K words |
| 2026-02-06 | 0001193125-26-041201 | EDGAR | — |
5 total filings indexed. 2 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001861123 |
| Ticker | EIKN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.eikontx.com |
| Listed | 2026-02-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report